Login to Your Account



Neurotrope shares swoon on weak signal in Alzheimer’s phase II

By Marie Powers
News Editor

Monday, May 1, 2017

Hope springs eternal in Alzheimer’s disease, and Neurotrope Inc. sought to keep that aspiration alive when reporting top-line data from its phase II study of bryostatin-1 in patients with moderate to severe AD.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription